Effects of astragaloside in treating myocardial injury and myocardial sarco/endoplasmic ca2+ -atpase of viral myocarditis mice

Abstract

To investigate the effects on myocardial injury and sarcoplasmic reticulum (SR) Ca(2+)-ATPase of viral myocarditis mice treated with Astragaloside (AS) and Astragalus Injection (AI). Viral myocarditis model was created by intraperitoneal inoculation with coxsackievirus B3m (CVB3m) solution and were divided into model, AS, AI and normal control groups. The mortality, myocardial pathological changes, serum cardiac troponin I (cTnI) and the activity of myocardial Sarco/Endoplasmic Ca(2+)-ATPase (SERCA) were observed. The mortality of model was higher than that of the normal control (P = 0.0042), AS and AI (P < 0.05). The serum level of cTnI of model was significantly higher than that of the normal control (P < 0.001), AS (P < 0.025) and AI (P < 0.05). The myocardial necrosis and inflammatory changes of AS and AI groups were alleviated than that of model (P < 0.01). The activity of myocardial SERCA of model were significantly lower than that of normal control (P < 0.001), AS (P < 0.01) and AI (P < 0.05). AS and AI have some protecting effects on myocardial injury of viral myocarditis mice. AS is the effective component of Astragalus membranaceus in treating viral myocarditis. One of the mechanisms of Astragalus membranaceus and AS for viral myocarditis mice depriving of the myocardial injury may be due to improve the activity of myocardial SERCA in the mice.